AT249840T - Methods and materials for preparation of modified antibody variable domains and their therapeutic use - Google Patents

Methods and materials for preparation of modified antibody variable domains and their therapeutic use

Info

Publication number
AT249840T
AT249840T AT93901238T AT93901238T AT249840T AT 249840 T AT249840 T AT 249840T AT 93901238 T AT93901238 T AT 93901238T AT 93901238 T AT93901238 T AT 93901238T AT 249840 T AT249840 T AT 249840T
Authority
AT
Austria
Prior art keywords
preparation
materials
methods
variable domains
therapeutic use
Prior art date
Application number
AT93901238T
Other languages
German (de)
Inventor
Gary M Studnicka
Roger G Ii Little
Dianne M Fishwild
Fred R Kohn
Original Assignee
Xoma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US80846491A priority Critical
Application filed by Xoma Corp filed Critical Xoma Corp
Priority to PCT/US1992/010906 priority patent/WO1993011794A1/en
Publication of AT249840T publication Critical patent/AT249840T/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/467Igs with modifications in the FR-residues only
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B30/00ICT specially adapted for sequence analysis involving nucleotides or amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/825Arthritis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/866Diabetes
AT93901238T 1991-12-13 1992-12-14 Methods and materials for preparation of modified antibody variable domains and their therapeutic use AT249840T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US80846491A true 1991-12-13 1991-12-13
PCT/US1992/010906 WO1993011794A1 (en) 1991-12-13 1992-12-14 Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
AT249840T true AT249840T (en) 2003-10-15

Family

ID=25198837

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93901238T AT249840T (en) 1991-12-13 1992-12-14 Methods and materials for preparation of modified antibody variable domains and their therapeutic use

Country Status (8)

Country Link
US (5) US5766886A (en)
EP (2) EP0571613B1 (en)
JP (3) JP4157160B2 (en)
AT (1) AT249840T (en)
CA (2) CA2507749C (en)
DE (2) DE69233204T2 (en)
ES (1) ES2202310T3 (en)
WO (1) WO1993011794A1 (en)

Families Citing this family (462)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US6774227B1 (en) * 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
CU22615A1 (en) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Process for obtaining less immunogenic murine monoclonal antibodies. monoclonal antibodies obtained
DE4425115A1 (en) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh A method for modifying the stability of antibodies
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
CA2257537C (en) * 1996-06-11 2005-01-25 Yeong Kuang Oon Iterative problem solving technique
US7084260B1 (en) 1996-10-10 2006-08-01 Genpharm International, Inc. High affinity human antibodies and human antibodies against human antigens
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
EP0983303B1 (en) * 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
WO1999037329A1 (en) * 1998-01-22 1999-07-29 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IT1306704B1 (en) * 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Monoclonal antibodies and synthetic and biotechnological derivatives ingrado to act as antagonist molecules for the ngf.
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
NZ562811A (en) 2000-08-07 2009-05-31 Centocor Inc Anti-TNF antibodies, compositions, methods and uses
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
AT489403T (en) 2000-10-02 2010-12-15 Novartis Vaccines & Diagnostic Human antibodies against CD40
US20030049800A1 (en) * 2000-12-15 2003-03-13 Saravis Calvin A. Compositions and methods for producing antibodies to low molecular weight analytes
JP4986370B2 (en) 2000-12-22 2012-07-25 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオMax−Planck−Gesellschaft zur Foerderung der Wissenschaften e.V. Use of Rgm and the modulator
EP2075256A2 (en) 2002-01-14 2009-07-01 William Herman Multispecific binding molecules
CA2454358A1 (en) * 2001-07-19 2003-07-31 Perlan Therapeutics, Inc. Multimeric proteins and methods of making and using same
US20040078837A1 (en) * 2001-08-02 2004-04-22 Shannon Mark E. Four human zinc-finger-containing proteins: MDZ3, MDZ4, MDZ7 and MDZ12
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
JP2007528691A (en) 2001-11-14 2007-10-18 セントカー・インコーポレーテツド Anti il-6 antibody, composition, methods and uses
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20080254027A1 (en) * 2002-03-01 2008-10-16 Bernett Matthew J Optimized CD5 antibodies and methods of using the same
WO2004033693A1 (en) 2002-03-29 2004-04-22 Xoma Technology Ltd. Methods vectors plasmids and methods for increasing expression of recombinant polypeptides
AU2003276832A1 (en) * 2002-05-10 2004-02-25 Medimmune, Llc EphA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
DK1534335T4 (en) 2002-08-14 2015-10-05 Macrogenics Inc Fcgammariib-specific antibodies, and methods of use thereof
EP3301114A1 (en) 2002-10-16 2018-04-04 Purdue Pharma LP Fusion polypeptides of antibodies that bind cell-associated ca 125/o722p
WO2004041865A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Stabilized single domain antibodies
US20110091451A1 (en) * 2002-11-15 2011-04-21 Kavanaugh William M Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β (1-42) oligomers, processes for their preparation and their use
US20050009097A1 (en) * 2003-03-31 2005-01-13 Better Marc D. Human engineered antibodies to Ep-CAM
WO2004092343A2 (en) * 2003-04-11 2004-10-28 Medimmune, Inc. Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution
JP2006524693A (en) * 2003-04-11 2006-11-02 メディミューン,インコーポレーテッド EphA2 and non-neoplastic hyperproliferative cell disorder
EP2316487B1 (en) 2003-04-11 2014-06-11 MedImmune, LLC Recombinant IL-9 antibodies & uses thereof
US8613922B2 (en) 2003-04-24 2013-12-24 The University Of North Carolina At Chapel Hill Methods for inhibiting diabetic retinopathy with an antibody against integrin associated protein (IAP)
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
DE602004029252D1 (en) 2003-06-13 2010-11-04 Biogen Idec Inc Aglycosyl anti-CD154 (CD40 ligand) antibodies and their uses
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
WO2005010163A2 (en) * 2003-07-15 2005-02-03 Barros Research Institute Compositions and methods for immunotherapy of human immunotherapy of human immunodeficiency virus (hiv)
JP2008500005A (en) * 2003-07-15 2008-01-10 バロス リサーチ インスティテュート Compositions and methods for immunotherapy of cancer and infectious diseases
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
JP2007511738A (en) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド Biomarkers and uses thereof osteoarthritis
CA2537055A1 (en) * 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US20060228355A1 (en) 2003-11-07 2006-10-12 Toon Laeremans Camelidae single domain antibodies vhh directed against epidermal growth factor receptor and uses therefor
KR101352853B1 (en) 2004-01-07 2014-02-04 조마 테크놀로지 리미티드 M-csf-specific monoclonal antibody and uses thereof
DK1718967T3 (en) 2004-02-03 2013-06-03 Diadexus Inc Methods for detecting Lp-PLA2 activity
CN1965082A (en) * 2004-02-06 2007-05-16 尼莫克斯股份有限公司 Humanized antibody
US7625549B2 (en) 2004-03-19 2009-12-01 Amgen Fremont Inc. Determining the risk of human anti-human antibodies in transgenic mice
EP2418224A3 (en) 2004-03-19 2013-07-24 Amgen Inc. Reducing the risk of human and anti-human antibodies through V gene manipulation
US6986264B1 (en) * 2004-07-15 2006-01-17 Carrier Corporation Economized dehumidification system
EP1791563A4 (en) 2004-07-26 2009-07-08 Biogen Idec Inc Anti-cd154 antibodies
AU2005286770A1 (en) 2004-09-21 2006-03-30 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
WO2006081171A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
US7402730B1 (en) 2005-02-03 2008-07-22 Lexicon Pharmaceuticals, Inc. Knockout animals manifesting hyperlipidemia
EP1846577B1 (en) 2005-02-07 2012-07-04 GeneNews Inc. Method of diagnosing osteoarthritis employing the biomarkers IL13RA1 and CPT1A
AU2006214121B9 (en) 2005-02-15 2013-02-14 Duke University Anti-CD19 antibodies and uses in oncology
US20090142338A1 (en) * 2005-03-04 2009-06-04 Curedm, Inc. Methods and Compositions for Treating Type 1 and Type 2 Diabetes Mellitus and Related Conditions
EP1858545A2 (en) * 2005-03-04 2007-11-28 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
EP1863531A1 (en) 2005-03-19 2007-12-12 Medical Research Council Improvements in or relating to treatment and prevention of viral infections
EP2371960A3 (en) * 2005-03-25 2012-01-11 National Research Council of Canada Method for isolation of soluble polypeptides
AU2006235276A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics Inc. CACNA1E in cancer diagnosis, detection and treatment
EP1871911A2 (en) 2005-04-07 2008-01-02 Chiron Corporation Cancer-related genes (prlr)
JP5838021B2 (en) 2005-04-15 2015-12-24 マクロジェニクス,インコーポレーテッド Covalent diabody and its use
JO3058B1 (en) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc Anti-IL-6 Antibodies,Compositions,Methods and uses
JP5047947B2 (en) 2005-05-05 2012-10-10 デューク ユニバーシティ Anti-cd19 antibody treatment for autoimmune disease
JP5065253B2 (en) 2005-05-06 2012-10-31 ザイモジェネティクス, インコーポレイテッド Il-31 monoclonal antibodies and their use
AT537188T (en) 2005-05-18 2011-12-15 Ablynx Nv Serum albumin-binding proteins
CA2609667C (en) 2005-05-25 2011-02-22 Curedm, Inc. Human proislet peptide, derivatives and analogs thereof, and methods of using same
PT2314623E (en) 2005-06-21 2012-10-02 Xoma Technology Ltd Il-1beta binding antibodies and fragments thereof
JP2008546805A (en) 2005-06-23 2008-12-25 メディミューン,エルエルシー Antibody preparation with optimal aggregation and fragmentation profile
EP2452694B1 (en) 2005-06-30 2018-11-14 Janssen Biotech, Inc. Anti-IL-23 antibodies, compositions, methods and uses
CN103145839A (en) * 2005-06-30 2013-06-12 Abbvie 公司 IL-12/P40 binding proteins
ES2538036T3 (en) * 2005-07-28 2015-06-16 Novartis Ag Use of antibody to M-CSF
JP5457671B2 (en) * 2005-07-28 2014-04-02 ノバルティス アーゲー M-csf-specific monoclonal antibodies and their use
JP5230420B2 (en) 2005-08-18 2013-07-10 ゲンマブ エー/エス Cd4 treatment with binding peptide and radiation
EP2500353A3 (en) 2005-08-19 2012-10-10 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090215992A1 (en) * 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007024715A2 (en) 2005-08-19 2007-03-01 Abbott Laboratories Dual variable domain immunoglobin and uses thereof
EP1928905B1 (en) 2005-09-30 2015-04-15 AbbVie Deutschland GmbH & Co KG Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
AU2006304883A1 (en) 2005-10-21 2007-04-26 Genenews Inc. Method and apparatus for correlating levels of biomarker products with disease
PT1954718E (en) 2005-11-30 2014-12-16 Abbvie Inc Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
AU2006320392B2 (en) 2005-11-30 2013-01-17 AbbVie Deutschland GmbH & Co. KG Monoclonal antibodies against amyloid beta protein and uses thereof
AU2006330411B2 (en) 2005-12-29 2012-07-12 Janssen Biotech, Inc. Human anti-IL-23 antibodies, compositions, methods and uses
CA2636149A1 (en) * 2006-01-05 2007-07-19 Novartis Ag Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
EP1999148B8 (en) 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
US8278421B2 (en) 2006-03-20 2012-10-02 Xoma Techolology Ltd. Human antibodies specific for gastrin materials and methods
WO2007117410A2 (en) 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CA2650126A1 (en) 2006-04-13 2007-10-25 Novartis Vaccines & Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer
TWI395754B (en) 2006-04-24 2013-05-11 Amgen Inc Humanized c-kit antibody
DK2027156T3 (en) 2006-06-02 2011-04-26 Aveo Pharmaceuticals Inc Hepatocyte growth factor (HGF) binding protein
KR101196184B1 (en) * 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. Hepatocyte growth factor hgf binding proteins
EP2037961B1 (en) 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
ES2599319T3 (en) 2006-06-26 2017-02-01 Macrogenics, Inc. Fc RIIB-specific antibodies and methods of use thereof
CA2656224C (en) 2006-06-26 2018-01-09 Macrogenics, Inc. Combination of fc.gamma.riib antibodies and cd20-specific antibodies and methods of use thereof
JP5829004B2 (en) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー/エス Anti-nkg2a antibody and its use
EP2420252A1 (en) 2006-08-04 2012-02-22 Novartis AG EPHB3-specific antibody and uses thereof
KR101433544B1 (en) 2006-08-18 2014-08-27 노바르티스 아게 Prlr-specific antibody and uses thereof
TW201343676A (en) 2006-08-28 2013-11-01 Kyowa Hakko Kirin Co Ltd Antagonistic human light-specific human monoclonal antibodies
CA2660175C (en) 2006-09-01 2015-05-12 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
KR101544108B1 (en) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 Binding protein interleukin -13
WO2008043018A1 (en) 2006-10-04 2008-04-10 Dana-Farber Cancer Institute, Inc. Tumor immunity
US8785400B2 (en) * 2006-11-22 2014-07-22 Curedm Group Holdings, Llc Methods and compositions relating to islet cell neogenesis
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
CN101678100A (en) 2006-12-06 2010-03-24 米迪缪尼有限公司 methods of treating systemic lupus erythematosus
EA200900767A1 (en) 2006-12-07 2009-12-30 Новартис Аг Antagonistic antibodies against ephb3
KR101503937B1 (en) 2006-12-08 2015-03-18 렉시컨 파마슈티컬스 인코퍼레이티드 Monoclonal antibodies against angptl3
RU2554747C9 (en) * 2006-12-20 2015-10-20 Ксома (Сша) Ллс Method of treating il-1beta-dependent diseases
US8435752B2 (en) * 2007-01-18 2013-05-07 University Of Southern California Gene polymorphisms predictive for dual TKI therapy
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
JP2010521180A (en) 2007-03-14 2010-06-24 ノバルティス アーゲー Treating cancer, APCDD1 inhibitor for the diagnosis or detection
WO2008121616A2 (en) 2007-03-30 2008-10-09 Medimmune, Inc. Antibodies with decreased deamidation profiles
US10280211B2 (en) 2007-05-04 2019-05-07 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Engineered rabbit antibody variable domains and uses thereof
CA2986531A1 (en) 2007-05-14 2008-11-27 Astrazeneca Ab Methods of reducing eosinophil levels
US20090175847A1 (en) * 2007-05-30 2009-07-09 Abbott Laboratories Humanized antibodies to ab (20-42) globulomer and uses thereof
US20090232801A1 (en) * 2007-05-30 2009-09-17 Abbot Laboratories Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof
CA2691434A1 (en) 2007-06-21 2008-12-24 Macrogenics, Inc. Covalent diabodies and uses thereof
KR20170012592A (en) 2007-08-23 2017-02-02 암젠 인크 Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
KR20100080519A (en) * 2007-08-30 2010-07-08 큐어디엠 인코포레이티드 Compositions and methods of using proislet peptides and analogs thereof
WO2009042962A2 (en) 2007-09-28 2009-04-02 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US20110212076A1 (en) * 2007-10-15 2011-09-01 King's College London Viral Therapeutic
JP2011500086A (en) * 2007-10-22 2011-01-06 シェーリング コーポレイションSchering Corporation Fully human anti-vegf antibodies and methods of use
US8663980B2 (en) 2007-10-26 2014-03-04 Janssen Biotech, Inc. Vectors, host cells, and methods of production and uses
AU2008324800B2 (en) 2007-11-05 2014-03-27 Astrazeneca Ab Methods of treating scleroderma
WO2009070642A1 (en) * 2007-11-28 2009-06-04 Medimmune, Llc Protein formulation
DK2796466T3 (en) 2007-12-07 2018-02-05 Zymogenetics Inc Humanized antibody molecules specific for IL-31
JP5591712B2 (en) 2007-12-14 2014-09-17 ノボ・ノルデイスク・エー/エス Antibody and its use for human nkg2d
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
WO2009088928A2 (en) * 2007-12-31 2009-07-16 Xoma Technology Ltd. Libraries, arrays and their uses for targeted affinity enhancement
JP2011509675A (en) 2008-01-18 2011-03-31 メディミューン,エルエルシー Cysteine ​​engineered antibodies for site-specific conjugation
CN101952317B (en) 2008-01-24 2015-07-22 诺沃-诺迪斯克有限公司 Humanized anti-human NKG2A monoclonal antibody
CA2711826C (en) 2008-01-25 2018-02-27 Amgen Inc. Ferroportin antibodies and methods of use
CN101952454B (en) 2008-02-08 2014-06-04 米迪缪尼有限公司 Anti-IFNAR1 antibodies with reduced Fc ligand affinity
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
WO2009121948A2 (en) * 2008-04-03 2009-10-08 Vib Vzw Single domain antibodies capable of modulating bace activity
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
KR20110014607A (en) 2008-04-29 2011-02-11 아보트 러보러터리즈 Dual variable domain immunoglobulins and uses thereof
EP2294087B1 (en) 2008-05-01 2014-05-14 Amgen, Inc. Anti-hepcidin antibodies and methods of use
AR071698A1 (en) 2008-05-09 2010-07-07 Abbott Gmbh & Co Kg Receptor antibodies of advanced glycosylation end products (RAGE) and uses thereof
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab Dual variable domain immunoglobulins and uses thereof
AU2009256072B2 (en) * 2008-06-06 2015-05-28 Xoma (Us) Llc Methods for the treatment of rheumatoid arthritis
US8747848B2 (en) 2008-06-20 2014-06-10 Novartis Ag Immunoglobulins with reduced aggregation
SG192489A1 (en) * 2008-07-08 2013-08-30 Abbott Lab Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
JP2011527579A (en) 2008-07-08 2011-11-04 アボット・ラボラトリーズAbbott Laboratories Prostaglandin e2 binding protein and the use
UA105009C2 (en) 2008-08-05 2014-04-10 Новартіс Аг Compositions and methods for antibodies targeting complement protein c5
CA2735939A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
WO2010065882A1 (en) * 2008-12-04 2010-06-10 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
SG10201407908VA (en) 2008-12-19 2015-01-29 Macrogenics Inc Covalent diabodies and uses thereof
EP2376122A2 (en) 2009-01-12 2011-10-19 Takeda Pharmaceutical Company Limited Agent for prophylaxis or treatment of cancer
EP2387584A1 (en) 2009-01-14 2011-11-23 IQ Therapeutics BV Combination antibodies for the treatment and prevention of disease caused by bacillus anthracis and related bacteria and their toxins
US20110165063A1 (en) * 2009-01-29 2011-07-07 Abbott Laboratories Il-1 binding proteins
EP2391652A4 (en) * 2009-01-29 2013-01-02 Abbott Lab Il-1 binding proteins
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en) 2009-02-24 2011-10-04 Abbott Laboratories Antibodies to troponin I and methods of use thereof
CA2752648A1 (en) 2009-03-05 2010-09-10 Abbott Laboratories Il-17 binding proteins
WO2010117729A1 (en) 2009-03-30 2010-10-14 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
AU2010256410B2 (en) 2009-06-04 2016-10-20 Massachusetts Institute Of Technology Methods for identification of sites for IgG conjugation
WO2010142603A1 (en) 2009-06-08 2010-12-16 Vib Vzw Screening for compounds that modulate gpr3-mediated beta-arrestin signaling and amyloid beta peptide generation
US8956614B2 (en) 2009-06-15 2015-02-17 Vib Vzw BACE1 inhibitory antibodies
MX2012000121A (en) 2009-06-22 2012-03-07 Medimmune Llc ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION.
EP2448593A2 (en) 2009-07-03 2012-05-09 Bionor Immuno AS Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
JP6163304B2 (en) 2009-07-15 2017-07-12 ポートラ ファーマシューティカルズ, インコーポレイテッド Unit dosage formulations of antidote of factor Xa inhibitors and methods of use thereof
US8318162B2 (en) * 2009-07-16 2012-11-27 Xoma Technology Ltd. Antibodies to high molecular weight melanoma associated antigen
DK2464657T3 (en) 2009-08-10 2015-06-29 Morphosys Ag New screening strategies to identify antibodies or fragments thereof that bind an antigen with enzymatic activity
WO2011020024A2 (en) 2009-08-13 2011-02-17 The Johns Hopkins University Methods of modulating immune function
CA2771575A1 (en) 2009-08-29 2011-03-03 Abbott Laboratories Therapeutic dll4 binding proteins
BR112012004710A2 (en) 2009-09-01 2016-08-16 Abbott Lab Dual variable domain immunoglobulins and use thereof
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
EP3187877A1 (en) 2009-09-25 2017-07-05 XOMA Technology Ltd. Screening methods
JP2013507928A (en) 2009-10-15 2013-03-07 アボット・ラボラトリーズAbbott Laboratories Dual variable domain immunoglobulin and uses thereof
UY32979A (en) * 2009-10-28 2011-02-28 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
US8420083B2 (en) * 2009-10-31 2013-04-16 Abbvie Inc. Antibodies to receptor for advanced glycation end products (RAGE) and uses thereof
CN105085681B (en) * 2009-12-02 2018-12-28 伊麦吉纳博公司 Target the J591 miniantibody and double antibody of human prostate-specific membrane antigen
US8790887B2 (en) 2009-12-04 2014-07-29 Vib Vzw Screening methods for compounds that modulate ARF-6 mediated endosomal redistribution
JP5951498B2 (en) * 2009-12-08 2016-07-13 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー Monoclonal antibodies to rgma proteins for use in the treatment of retinal nerve fiber layer degeneration
HUE030208T2 (en) 2009-12-10 2017-04-28 Regeneron Pharma Mice that make heavy chain antibodies
EP2332995A1 (en) 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
MX2012006626A (en) 2009-12-22 2012-06-25 Hoffmann La Roche Sequence dependent aggregation.
DK2528944T3 (en) 2010-01-29 2015-09-14 Morphosys Ag Rodent combinatorial antibody libraries
CN102933231B (en) 2010-02-10 2015-07-29 伊缪诺金公司 Cd20 antibody and uses thereof
PT2538976T (en) 2010-02-24 2017-03-08 Immunogen Inc Immunoconjugates against folate receptor 1 and uses thereof
MX348312B (en) 2010-03-02 2017-06-06 Abbvie Inc Therapeutic dll4 binding proteins.
WO2011123507A1 (en) 2010-03-30 2011-10-06 Centocor Ortho Biotech Inc. Humanized il-25 antibodies
SG184452A1 (en) 2010-04-09 2012-11-29 Aveo Pharmaceuticals Inc Anti-erbb3 antibodies
WO2011127580A1 (en) 2010-04-14 2011-10-20 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
CA2796339A1 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CN102883748A (en) 2010-05-07 2013-01-16 爱克索马技术有限公司 Methods for the treatment of IL-1beta related conditions
KR101539683B1 (en) 2010-05-14 2015-07-30 애브비 인코포레이티드 Il-1 binding proteins
WO2011156617A2 (en) 2010-06-09 2011-12-15 Aveo Pharmaceuticals, Inc. Anti-egfr antibodies
WO2012003472A1 (en) 2010-07-02 2012-01-05 Aveo Pharmaceuticals, Inc. Anti-notch1 antibodies
CA2804399A1 (en) 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
US20120009196A1 (en) 2010-07-08 2012-01-12 Abbott Laboratories Monoclonal antibodies against hepatitis c virus core protein
UY33492A (en) 2010-07-09 2012-01-31 Abbott Lab Immunoglobulins Dual variable domain and uses thereof
SG187682A1 (en) 2010-08-02 2013-03-28 Macrogenics Inc Covalent diabodies and uses thereof
JP2013537415A (en) 2010-08-03 2013-10-03 アッヴィ・インコーポレイテッド Dual variable domain immunoglobulin and uses thereof
US8956859B1 (en) 2010-08-13 2015-02-17 Aviex Technologies Llc Compositions and methods for determining successful immunization by one or more vaccines
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.
AU2011291462A1 (en) 2010-08-19 2013-03-14 Zoetis Belgium S.A. Anti-NGF antibodies and their use
MX2013002270A (en) 2010-08-26 2013-05-14 Abbvie Inc Dual variable domain immunoglobulins and uses thereof.
ES2664989T3 (en) 2010-10-01 2018-04-24 National Research Council Of Canada CEACAM6 antibodies and uses thereof
EP2632949B1 (en) 2010-10-25 2017-09-13 National Research Council of Canada Clostridium difficile-specific antibodies and uses thereof
WO2012075111A1 (en) 2010-11-30 2012-06-07 Novartis Ag Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012088094A2 (en) 2010-12-21 2012-06-28 Abbott Laboratories Il-1 binding proteins
EP2655417A2 (en) 2010-12-21 2013-10-30 AbbVie Inc. Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
KR20130133212A (en) 2010-12-23 2013-12-06 인터셀 오스트리아 아게 Oprf/i agents and their use in hospitalized and other patients
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
WO2012110500A1 (en) 2011-02-15 2012-08-23 Vib Vzw Means and methods for improvement of synaptic dysfunction disorders
SG194111A1 (en) 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
CN103608040B (en) 2011-04-20 2017-03-01 米迪缪尼有限公司 B7-h1 binding antibodies and other molecules of pd-1
MX2013013187A (en) 2011-05-10 2014-03-21 Amgen Inc Methods of treating or preventing cholesterol related disorders.
CN104080804B (en) 2011-05-21 2017-06-09 宏观基因有限公司 Deimmunized serum binding domain and uses extended serum half-life
NZ618757A (en) 2011-06-03 2016-06-24 Xoma Technology Ltd Antibodies specific for tgf-beta
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
DK3006464T3 (en) 2011-06-10 2018-09-17 Canada Minister Nat Defence Antiricin antibodies and uses thereof
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
EP2731970B1 (en) 2011-07-15 2018-11-28 MorphoSys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (mif) and d-dopachrome tautomerase (d-dt)
US9156911B2 (en) 2011-07-18 2015-10-13 Amgen Inc. Apelin antigen-binding proteins and uses thereof
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
EP3348575A1 (en) 2011-08-16 2018-07-18 Emory University Jaml specific binding agents, antibodies, and uses related thereto
CA2849705A1 (en) 2011-09-23 2013-03-28 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Modified albumin-binding domains and uses thereof to improve pharmacokinetics
JP2014530816A (en) 2011-10-14 2014-11-20 ノバルティスアーゲー Antibodies and methods for Wnt pathway related disease
TW201323440A (en) 2011-10-24 2013-06-16 Abbvie Inc Immunobinders directed against sclerostin
WO2013063419A2 (en) 2011-10-28 2013-05-02 The Trustees Of The University Of Pennsylvania A fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
EP2773651A4 (en) 2011-11-03 2015-08-12 Univ Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
SG11201402536PA (en) 2011-11-23 2014-06-27 Medimmune Llc Binding molecules specific for her3 and uses thereof
EP2791175A2 (en) 2011-12-14 2014-10-22 Abbvie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
CA2855840A1 (en) 2011-12-14 2013-06-20 AbbVie Deutschland GmbH & Co. KG Composition and method for the diagnosis and treatment of iron-related disorders
JP6320300B2 (en) 2011-12-19 2018-05-09 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー Methods for the treatment of acne
WO2013093762A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
FR2984750B1 (en) 2011-12-23 2014-01-10 Lfb Biotechnologies Novel pharmaceutical compositions comprising an antibody binding the human receptor of the type of anti-Mullerian hormone ii
US9717803B2 (en) 2011-12-23 2017-08-01 Innate Pharma Enzymatic conjugation of polypeptides
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
UY34558A (en) 2011-12-30 2013-07-31 Abbvie Inc Dual specific binding proteins directed against IL-13 and / or IL-17
US20150011431A1 (en) 2012-01-09 2015-01-08 The Scripps Research Institute Humanized antibodies
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
CN104507967B (en) 2012-01-20 2018-10-12 建新公司 Anti-cxcr3 antibody
DK2807192T3 (en) 2012-01-27 2018-07-23 Abbvie Deutschland A composition and method for the diagnosis and treatment of diseases associated with neuritdegeneration
CN104379602B (en) 2012-03-08 2017-05-03 哈洛齐梅公司 Anti-EGFR antibodies and use conditional activity
WO2013136193A2 (en) 2012-03-16 2013-09-19 University Health Network Methods and compositions for modulating toso activity
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20140030270A1 (en) 2012-05-03 2014-01-30 Amgen Inc. Methods of treating or preventing cholesterol related disorders
CA2875624A1 (en) 2012-06-06 2013-12-12 Bionor Immuno As Hiv vaccine
US9617334B2 (en) 2012-06-06 2017-04-11 Zoetis Services Llc Caninized anti-NGF antibodies and methods thereof
EP2859114B1 (en) 2012-06-11 2019-05-15 Amgen, Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
TW201402608A (en) 2012-07-12 2014-01-16 Abbvie Inc IL-1 binding proteins
EA201590208A1 (en) 2012-07-13 2015-11-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания Upregulation car T-cells by co-administration of bispecific antibody
EP2872894B1 (en) 2012-07-13 2019-04-17 Innate Pharma Screening of conjugated antibodies
TWI596113B (en) 2012-07-25 2017-08-21 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN104995517B (en) 2012-08-17 2018-07-17 莫佛塞斯公司 Complex-specific antibodies and antibody fragments and uses thereof
SG11201500938XA (en) 2012-08-31 2015-04-29 Immunogen Inc Diagnostic assays and kits for detection of folate receptor 1
EP2904106A4 (en) 2012-10-01 2016-05-11 Univ Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
AU2013334451A1 (en) 2012-10-24 2015-06-04 National Research Council Of Canada Anti-Campylobacter jejuni antibodies and uses therefor
PE11792015A1 (en) 2012-11-01 2015-09-12 Abbvie Inc Dual variable domain immunoglobulins anti-vegf / Dll4 and uses thereof
WO2014072482A1 (en) 2012-11-09 2014-05-15 Innate Pharma Recognition tags for tgase-mediated conjugation
US9365646B2 (en) 2012-12-05 2016-06-14 Novartis Ag Compositions and methods for antibodies targeting EPO
US9383357B2 (en) 2012-12-07 2016-07-05 Northwestern University Biomarker for replicative senescence
EA201591176A1 (en) 2012-12-18 2016-02-29 Новартис Аг Compositions and methods using a peptide tag binds to hyaluronan
US9879083B2 (en) 2012-12-19 2018-01-30 Aveo Pharmaceuticals, Inc. Anti-Notch3 antibodies
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US9873733B2 (en) 2012-12-20 2018-01-23 Morphosys Ag. Anti-staphylococcal antibodies
MX2015007751A (en) 2012-12-21 2015-11-30 Aveo Pharmaceuticals Inc Anti-gdf15 antibodies.
WO2014100542A1 (en) 2012-12-21 2014-06-26 Abbvie, Inc. High-throughput antibody humanization
KR20150100715A (en) 2012-12-21 2015-09-02 앰플리뮨, 인크. Anti-h7cr antibodies
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for modulating regulatory and effector t cells
WO2015198217A2 (en) 2013-02-08 2015-12-30 Novartis Ag Compositions and methods for long-acting antibodies targeting il-17
MA38322B1 (en) 2013-02-08 2018-09-28 Novartis Ag anti-IL-17 and their use in the treatment of autoimmune and inflammatory disorders antibody
CN105358576A (en) 2013-02-20 2016-02-24 诺华股份有限公司 Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
EP2958942A1 (en) 2013-02-20 2015-12-30 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP2970947A4 (en) 2013-03-14 2016-10-12 Abbott Lab Hcv ns3 recombinant antigens and mutants thereof for improved antibody detection
US9371374B2 (en) 2013-03-14 2016-06-21 Abbott Laboratories HCV core lipid binding domain monoclonal antibodies
US9194873B2 (en) 2013-03-14 2015-11-24 Abbott Laboratories HCV antigen-antibody combination assay and methods and compositions for use therein
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
JP2016525874A (en) 2013-03-15 2016-09-01 サッター ベイ ホスピタルズ falz for use as a target for therapy for the treatment of cancer
MX2015013166A (en) 2013-03-15 2015-12-11 Abbvie Inc Dual specific binding proteins directed against il-1 beta and il-17.
US9469686B2 (en) 2013-03-15 2016-10-18 Abbott Laboratories Anti-GP73 monoclonal antibodies and methods of obtaining the same
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag Cancer treatment using a chimeric receptor antigen anti-CD19
US20160060347A1 (en) 2013-04-17 2016-03-03 Morphosys Ag Antibodies targeting specifically human cxcr2
CN106414489A (en) 2013-05-24 2017-02-15 米迪缪尼有限公司 Anti-b7-h5 antibodies and their uses
US10100123B2 (en) 2013-06-06 2018-10-16 Pierre Fabre Medicament Anti-C10orf54 antibodies and uses thereof
US10183988B2 (en) 2013-06-07 2019-01-22 Duke University Anti-Complement factor H antibodies
EP3010547A1 (en) 2013-06-20 2016-04-27 Innate Pharma Enzymatic conjugation of polypeptides
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
KR20160042871A (en) 2013-06-21 2016-04-20 이나뜨 파르마, 에스.아. Enzymatic conjugation of polypeptides
AR096601A1 (en) 2013-06-21 2016-01-20 Novartis Ag 1 receptor antibodies lectin-like oxidized LDL and methods of use
AU2013396206A1 (en) 2013-06-28 2016-01-21 Amgen Inc. Methods for treating homozygous familial hypercholesterolema
US20160159928A1 (en) 2013-07-18 2016-06-09 Fabrus, Inc. Humanized antibodies with ultralong complementary determining regions
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
WO2015007337A1 (en) 2013-07-19 2015-01-22 Bionor Immuno As Method for the vaccination against hiv
CN104418947A (en) 2013-09-11 2015-03-18 香港大学 Anti-her2 and anti-igf-ir bi-specific antibodies and uses thereof
EP3044236A2 (en) 2013-09-12 2016-07-20 Halozyme, Inc. Modified anti-epidermal growth factor receptor antibodies and methods of use thereof
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
EA201691078A1 (en) 2013-12-06 2017-01-30 Дана-Фарбер Кэнсер Инститьют, Инк. therapeutic peptides
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
WO2015097536A2 (en) 2013-12-24 2015-07-02 Janssen Pharmaceutical Nv Anti-vista antibodies and fragments
US20160340406A1 (en) 2014-01-21 2016-11-24 Novartis Ag Enhanced antigen presenting ability of rna car t cells by co-introduction of costimulatory molecules
EP3102701A1 (en) 2014-02-07 2016-12-14 Novartis AG Impact of genetic factors on disease progression and response to anti-c5 antibody in geographic atrophy
AU2016227493A1 (en) 2015-03-03 2017-06-08 Kymab Limited Antibodies, uses & methods
WO2015131257A1 (en) 2014-03-06 2015-09-11 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
CN106536555A (en) 2014-03-06 2017-03-22 加拿大国家研究委员会 Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
US10106614B2 (en) 2014-03-06 2018-10-23 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
CN106456728A (en) 2014-03-14 2017-02-22 达纳-法伯癌症研究所公司 Vaccine compositions and methods for restoring NKG2D pathway function against cancers
WO2015142675A2 (en) 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
SG11201606909RA (en) 2014-04-07 2016-10-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
CN106232139A (en) 2014-04-11 2016-12-14 免疫医疗有限责任公司 Bispecific her2 antibodies
GB201406767D0 (en) 2014-04-15 2014-05-28 Cancer Rec Tech Ltd Humanized anti-Tn-MUC1 antibodies anf their conjugates
US9388239B2 (en) 2014-05-01 2016-07-12 Consejo Nacional De Investigation Cientifica Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CA2945822A1 (en) 2014-05-21 2015-11-26 Dana-Farber Cancer Institute, Inc. Methods for treating cancer with anti bip or anti mica antibodies
MX2016015614A (en) 2014-05-28 2017-08-21 Agenus Inc Anti-gitr antibodies and methods of use thereof.
MX2016016826A (en) 2014-06-20 2017-08-28 Aveo Pharmaceuticals Inc Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator.
JP2017519765A (en) 2014-06-20 2017-07-20 アベオ ファーマシューティカルズ, インコーポレイテッド Gdf15 regulators of congestive heart failure and other cardiac dysfunction using therapeutic
US20170290876A1 (en) 2014-06-25 2017-10-12 Novartis Ag Compositions and methods for long acting proteins
EP3160991A2 (en) 2014-06-25 2017-05-03 Novartis AG Compositions and methods for long acting proteins
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9150660B1 (en) 2014-07-15 2015-10-06 Kymab Limited Precision Medicine by targeting human NAV1.8 variants for treatment of pain
US9067998B1 (en) 2014-07-15 2015-06-30 Kymab Limited Targeting PD-1 variants for treatment of cancer
US9023359B1 (en) 2014-07-15 2015-05-05 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9045548B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment
US9034332B1 (en) 2014-07-15 2015-05-19 Kymab Limited Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment
US8986694B1 (en) 2014-07-15 2015-03-24 Kymab Limited Targeting human nav1.7 variants for treatment of pain
US8945560B1 (en) 2014-07-15 2015-02-03 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US9045545B1 (en) 2014-07-15 2015-06-02 Kymab Limited Precision medicine by targeting PD-L1 variants for treatment of cancer
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
US9051378B1 (en) 2014-07-15 2015-06-09 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US8992927B1 (en) 2014-07-15 2015-03-31 Kymab Limited Targeting human NAV1.7 variants for treatment of pain
US20170211055A1 (en) 2014-07-21 2017-07-27 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
EP3174557B1 (en) 2014-07-29 2018-10-17 Cellectis Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy
SG11201700473QA (en) 2014-08-07 2017-02-27 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
US20170275374A1 (en) 2014-09-04 2017-09-28 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
WO2016043577A1 (en) 2014-09-16 2016-03-24 Academisch Medisch Centrum Ig-like molecules binding to bmp4
AU2015317608A1 (en) 2014-09-17 2017-04-06 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
US10098973B2 (en) 2014-10-10 2018-10-16 National Research Council Of Canada Anti-tau antibody and uses thereof
CA2967118A1 (en) 2014-11-10 2016-05-19 Medimmune Limited Binding molecules specific for cd73 and uses thereof
JP2017535264A (en) 2014-11-12 2017-11-30 ライナット ニューロサイエンス コーポレイション Inhibitory chimeric antigen receptor
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016094881A2 (en) 2014-12-11 2016-06-16 Abbvie Inc. Lrp-8 binding proteins
UY36449A (en) 2014-12-19 2016-07-29 Novartis Ag Compositions and methods for antibodies directed to BMP6
US10239942B2 (en) 2014-12-22 2019-03-26 Pd-1 Acquisition Group, Llc Anti-PD-1 antibodies
CN108495641A (en) 2015-08-11 2018-09-04 塞勒克提斯公司 Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
US20180044424A1 (en) 2015-02-02 2018-02-15 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN108136001A (en) 2015-04-03 2018-06-08 佐马技术有限公司 Treatment of cancer using inhibitors of tgf-beta and pd-1
SG11201708220RA (en) 2015-04-07 2017-11-29 Alector Llc Anti-sortilin antibodies and methods of use thereof
US20180140602A1 (en) 2015-04-07 2018-05-24 Novartis Ag Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
RU2017134652A (en) 2015-04-08 2019-04-09 Новартис Аг Cd20 therapy, CD22 therapy, and combination therapy with cells expressing the chimeric antigen receptor (car) k cd19
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
JP2018515603A (en) 2015-05-04 2018-06-14 ビオノル・イムノ・アクシェセルスカプBionor Immuno AS The dosage regimen for Hiv vaccine
AU2016256911A1 (en) 2015-05-07 2017-11-16 Agenus Inc. Anti-OX40 antibodies and methods of use thereof
KR20180029201A (en) 2015-05-18 2018-03-20 티씨알2 테라퓨틱스 인크. Compositions and methods for reprogramming tcr using the fusion protein
US20180237520A1 (en) * 2015-06-01 2018-08-23 Medigene Immuniotherapies Gmbh Method for generating antibodies against t cell receptor
PE00412018A1 (en) 2015-06-05 2018-01-09 Novartis Ag Antibodies directed to the bone morphogenetic protein (BMP9) and methods from these
TW201710286A (en) 2015-06-15 2017-03-16 Abbvie Inc Binding proteins against VEGF, PDGF, and/or their receptors
CN107922497A (en) 2015-06-24 2018-04-17 詹森药业有限公司 Anti-VISTA antibodies and fragments
UY36751A (en) 2015-06-26 2017-01-31 Novartis Ag Xi factor antibodies and methods of use
AU2016285552A1 (en) 2015-06-29 2018-01-18 Immunogen, Inc. Anti-CD123 antibodies and conjugates and derivatives thereof
US10287338B2 (en) 2015-07-10 2019-05-14 Miran NERSISSIAN Factor VIII protein compositions and methods of treating of hemophilia A
CA2994516A1 (en) 2015-08-03 2017-02-09 Novartis Ag Methods of treating fgf21-associated disorders
JP2018532693A (en) 2015-08-06 2018-11-08 ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー Their use for the treatment of antibody fragments and hypoglycemia for insulin receptor
US20180230193A1 (en) 2015-08-07 2018-08-16 Andreas Loew Treatment of cancer using chimeric cd3 receptor proteins
CN107949573A (en) 2015-09-01 2018-04-20 艾吉纳斯公司 Anti-PD-1 antibodies and methods of use thereof
AU2016370813A1 (en) 2015-12-18 2018-06-28 Novartis Ag Antibodies targeting CD32b and methods of use thereof
CN109195988A (en) 2016-01-10 2019-01-11 尼奥克斯医疗有限公司 For enhancing the method and composition of the immunotherapy for cancer effect of super antigen mediation
EP3405492A1 (en) 2016-01-21 2018-11-28 Novartis AG Multispecific molecules targeting cll-1
CN109069626A (en) 2016-02-12 2018-12-21 詹森药业有限公司 Anti- VISTA (B7H5) antibody
KR20180118175A (en) 2016-03-04 2018-10-30 노파르티스 아게 Cells expressing multiple chimeric antigen receptor (CAR) molecules and their uses
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
WO2017165683A1 (en) 2016-03-23 2017-09-28 Novartis Ag Cell secreted minibodies and uses thereof
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
SG11201809041TA (en) 2016-04-15 2018-11-29 Novartis Ag Compositions and methods for selective protein expression
WO2017189724A1 (en) 2016-04-27 2017-11-02 Novartis Ag Antibodies against growth differentiation factor 15 and uses thereof
TW201802121A (en) 2016-05-25 2018-01-16 Novartis Ag Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
EP3464360A1 (en) 2016-05-27 2019-04-10 Agenus Inc. Anti-tim-3 antibodies and methods of use thereof
EP3464318A1 (en) 2016-06-02 2019-04-10 AbbVie Inc. Glucocorticoid receptor agonist and immunoconjugates thereof
WO2017210617A2 (en) 2016-06-02 2017-12-07 Porter, David, L. Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
AU2017279550A1 (en) 2016-06-08 2019-01-03 Abbvie Inc. Anti-B7-H3 antibodies and antibody drug conjugates
EP3468993A1 (en) 2016-06-08 2019-04-17 AbbVie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
CN109641962A (en) 2016-06-08 2019-04-16 艾伯维公司 Anti- B7-H3 antibody and antibody drug conjugates
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
AU2017283787A1 (en) 2016-06-15 2019-01-24 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
EP3472210A1 (en) 2016-06-17 2019-04-24 Life Technologies Corporation Site-specific crosslinking of antibodies
EP3481864A1 (en) 2016-07-08 2019-05-15 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
CA3030837A1 (en) 2016-07-15 2018-01-18 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
EP3491016A1 (en) 2016-07-28 2019-06-05 Novartis AG Combination therapies of chimeric antigen receptors and pd-1 inhibitors
WO2018026819A2 (en) 2016-08-01 2018-02-08 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
WO2018026748A1 (en) 2016-08-01 2018-02-08 Xoma (Us) Llc Parathyroid hormone receptor 1 (pth1r) antibodies and uses thereof
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109562153A (en) 2016-08-07 2019-04-02 诺华股份有限公司 The immunization method that mRNA is mediated
KR20190057113A (en) 2016-09-28 2019-05-27 조마 (유에스) 엘엘씨 Antibodies Binding to Interleukin-2 and Their Uses
CA3036717A1 (en) 2016-10-03 2018-04-12 Abbott Laboratories Improved methods of assessing gfap status in patient samples
WO2018067754A1 (en) 2016-10-04 2018-04-12 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
CA3036745A1 (en) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions and methods for t-cell receptors reprogramming using fusion proteins
KR20190057366A (en) 2016-10-07 2019-05-28 노파르티스 아게 Chimeric antigen receptor for the treatment of cancer
AU2017343621A1 (en) 2016-10-11 2019-04-11 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018098363A2 (en) 2016-11-23 2018-05-31 Bioverativ Therapeutics Inc. Bispecific antibodies binding to coagulation factor ix and coagulation factor x
WO2018106862A1 (en) 2016-12-07 2018-06-14 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
WO2018116267A2 (en) 2016-12-23 2018-06-28 Novartis Ag Methods of treatment with anti-factor xi/xia antibodies
AU2017383232A1 (en) 2016-12-23 2019-06-27 Novartis Ag Factor XI antibodies and methods of use
WO2018129078A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Dnabii vaccines and antibodies with enhanced activity
WO2018129092A1 (en) 2017-01-04 2018-07-12 Research Institute At Nationwide Children's Hospital Antibody fragments for the treatment of biofilm-related disorders
TW201825515A (en) 2017-01-04 2018-07-16 美商伊繆諾金公司 Met antibody and immune conjugate and uses
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018146594A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
WO2018170178A1 (en) 2017-03-15 2018-09-20 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2018175942A1 (en) 2017-03-23 2018-09-27 Abbott Laboratories Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
US20180306812A1 (en) 2017-04-15 2018-10-25 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
US20180313838A1 (en) 2017-04-28 2018-11-01 Abbott Laboratories Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
WO2018204363A1 (en) 2017-05-01 2018-11-08 Agenus Inc. Anti-tigit antibodies and methods of use thereof
WO2018218169A1 (en) 2017-05-25 2018-11-29 Abbott Laboratories Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
WO2018222783A1 (en) 2017-05-30 2018-12-06 Abbott Laboratories Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin i and early biomarkers
WO2018224441A1 (en) 2017-06-05 2018-12-13 Numab Innovation Ag Novel anti-cd3 antibodies
WO2018232020A1 (en) 2017-06-13 2018-12-20 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018229706A1 (en) 2017-06-16 2018-12-20 Novartis Ag Combination therapy for the treatment of cancer
WO2019010131A1 (en) 2017-07-03 2019-01-10 Abbott Laboratories Improved methods for measuring ubiquitin carboxy-terminal hydrolase l1 levels in blood
WO2019025299A1 (en) 2017-07-31 2019-02-07 F. Hoffmann-La Roche Ag Three-dimensional structure-based humanization method
WO2019051164A1 (en) 2017-09-07 2019-03-14 Augusta University Research Institute, Inc. Antibodies to programmed cell death protein 1
WO2019070161A2 (en) 2017-10-04 2019-04-11 Opko Pharmaceuticals, Llc Articles and methods directed to personalized therapy of cancer
US20190144549A1 (en) 2017-10-10 2019-05-16 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
WO2019072869A1 (en) 2017-10-10 2019-04-18 Numab Innovation Ag Antibodies targeting pdl1 and methods of use thereof
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
WO2019072868A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Multispecific antibody
WO2019072870A1 (en) 2017-10-10 2019-04-18 Numab Innovation Ag Antibodies targeting cd137 and methods of use thereof
EP3470429A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting pdl1 and methods of use thereof
WO2019087115A1 (en) 2017-10-31 2019-05-09 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
WO2019102353A1 (en) 2017-11-22 2019-05-31 Novartis Ag Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
WO2019112860A1 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of gfap and uch-l1
WO2019113525A2 (en) 2017-12-09 2019-06-13 Abbott Laboratories Methods for aiding in the diagnosis and evaluation of a subject who has sustained an orthopedic injury and that has or may have sustained an injury to the head, such as mild traumatic brain injury (tbi), using glial fibrillary acidic protein (gfap) and/or ubiquitin carboxy-terminal hydrolase l1 (uch-l1)

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4391904A (en) * 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0173494A3 (en) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4888415A (en) * 1985-03-04 1989-12-19 Dana-Farber Cancer Institute, Inc. Gelonin immunotoxin
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
KR950009089B1 (en) * 1986-08-18 1995-08-14 샘 제이. 밀스타인 Delivery systems for pharmaceutical agents
US4853871A (en) * 1987-04-06 1989-08-01 Genex Corporation Computer-based method for designing stablized proteins
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0407399A4 (en) * 1988-02-03 1991-06-19 Xoma Corporation Immunosupression with anti-pan t-cell immunotoxin compositions
EP0397798A4 (en) * 1988-02-03 1991-10-30 Xoma Corporation Therapeutic use of anti-t cell immunotoxin for autoimmune diseases
WO1989009622A1 (en) * 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
IL162181A (en) * 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5101025A (en) * 1989-04-04 1992-03-31 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5614192A (en) * 1989-07-19 1997-03-25 Connective Therapeutics, Inc. T cell receptor peptides as therapeutics for immune-related disease
NZ236792A (en) * 1990-01-19 1993-05-26 Merck & Co Inc Recombinant human anti-cd18 antibody, murine 1b4 heavy or light chain variable region, dna, vectors, mammalian host and pharmaceutical compositions
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
US5858725A (en) * 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
WO1992015327A1 (en) * 1991-03-08 1992-09-17 Protein Design Labs, Inc. Recombinant double chain immunotoxins
EP0519596B1 (en) * 1991-05-17 2005-02-23 Merck & Co., Inc. A method for reducing the immunogenicity of antibody variable domains
LU91067I2 (en) * 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and derivatives chemical immuno including immotoxines
AU2238292A (en) * 1991-06-14 1993-01-12 Xoma Corporation Microbially-produced antibody fragments and their conjugates
RU2142015C1 (en) * 1991-09-06 1999-11-27 Рисерч Дивелопмент Фаундейшн Dna fragment encoding protein gelonin and method of its producing, vector providing protein gelonin expression, recombinant strain escherichia coli - producer of protein gelonin
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies

Also Published As

Publication number Publication date
US20040005630A1 (en) 2004-01-08
EP0571613A4 (en) 1997-03-05
EP0571613B1 (en) 2003-09-17
US5766886A (en) 1998-06-16
EP0571613A1 (en) 1993-12-01
JPH06506362A (en) 1994-07-21
US20050239141A1 (en) 2005-10-27
CA2103887A1 (en) 1993-06-14
EP1291360A1 (en) 2003-03-12
WO1993011794A1 (en) 1993-06-24
JP2008253267A (en) 2008-10-23
US5821123A (en) 1998-10-13
DE69233204T2 (en) 2004-07-15
JP4157160B2 (en) 2008-09-24
JP2005160485A (en) 2005-06-23
CA2507749C (en) 2010-08-24
DE69233204D1 (en) 2003-10-23
CA2507749A1 (en) 1993-06-24
CA2103887C (en) 2005-08-30
US5770196A (en) 1998-06-23
ES2202310T3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
DE69322225T2 (en) Polymerisationskatalysatore and methods for the preparation of polymers
DE69227208T2 (en) Apparatus for simultaneously wet treatment of multiple samples and their use
DE69208565D1 (en) Catalyst and process for the preparation of nitriles
DE3888224D1 (en) Determination of tumor necrosis factor; monoclonal antibodies and composition.
DE69526636D1 (en) Purified hepatitis C virus coat proteins for diagnostic and therapeutic use
DE59310263D1 (en) A method for the determination of materials and / or their properties and device therefor
DE69819332D1 (en) IMPROVED ANTIBODIES TO IgE AND METHOD FOR IMPROVEMENT OF ANTIBODIES
DE69312181T2 (en) Hydrogel compositions and methods of preparation thereof
AT184539T (en) Method and vorrichten for the extrusion of Bingham materials
DE59608937D1 (en) Dermatological and use of semi-fluorinated alkanes for the preparation of dermatological
DE69324859D1 (en) Use of lipid-bound Glykoaminoglykanen for the treatment of rheumatoid arthritis
DE69326937D1 (en) Combination of anti-hormonal and binding molecules for cancer treatment
DE69032429D1 (en) Compounds of metal-peptides and cosmetic methods for stimulating hair growth
DE69434465D1 (en) A method for regulating the immune response through the use of CTLA4-binding molecules and IL4-binding molecules
DE69306114T2 (en) Use of tissue adhesion in situ modification of alginate for the prevention of
DE68922808D1 (en) Monoclonal antibodies against the receptor of the epidermal growth factor and those containing therapeutic preparations.
FI941572A0 (en) The anti-erbB-2 monoclonal combination and the method of use of antibodies
DE69031413D1 (en) Metal complex compounds, methods of making and methods of using
AT424559T (en) Test for rapid determination of ischemic states and test set for
DE69331176T2 (en) Bone cement and process for its preparation
DE69019976D1 (en) Method and medium for the determination of polyhydroxyl compounds.
DE69317647T2 (en) User interface for easy setting of rechnerlautstaerke and high savings levels
DE69431358D1 (en) Methods and compositions for microencapsulation of adjuvants
DE69229566T2 (en) Composition and method for delivery of drugs
DE69124357T2 (en) Protein nanomatrixes and methods for preparing

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties